Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
IsoPlexis logo — Powerful Biology Accelerating the Future of Medicine

IsoPlexis

Powerful Biology Accelerating the Future of Medicine

Founded 2013 United States Branford, United States 65 employees Series D Total: $205.10M Biotechnology, Health Care +2

General Information

Company Name IsoPlexis
Founded Year 2013
Location United States Branford, United States
Employees 65
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Series D
Business Model B2B, Platform, SaaS
Revenue Model Product Sales, Subscription, Usage Based
Social

BounceWatch is an independent company data service, not affiliated with IsoPlexis. To contact IsoPlexis, visit isoplexis.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does IsoPlexis compare?

A PDF of IsoPlexis and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting IsoPlexis soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About IsoPlexis

IsoPlexis, founded in 2013, is a pioneering company in the fields of Biotechnology, Health Care, Health and Wellness, and Medical Devices. Headquartered in the United States, IsoPlexis is at the forefront of transforming immune medicine with their innovative, high-resolution systems designed to enhance the development and personalization of curative medicines. Their mission is encapsulated in their slogan: "Powerful Biology Accelerating the Future of Medicine."

The company has recently demonstrated its growth potential through a significant $85.00M Series D investment, secured on 07 January 2021. This latest funding round was backed by prominent investors including BlackRock, Ally Bridge Group, and Perceptive Advisors. This strong backing from leading investment groups underscores IsoPlexis's promising role in spearheading advancements in immune medicine, which appeals greatly to venture capitalists seeking impactful and innovative companies in the health tech sector.

Business keywords: Life Science Technology, Single-Cell Detection, Immune Medicine, Curative Medicines, High Resolution Systems, Therapeutic Development, Personalized Medicine, Immune Response Analysis, Disease Monitoring, Microfluidics, Immune Monitoring, Therapeutic Efficacy Assessment, Safety Assessment, Disease Progression Monitoring, Physician Decision Support

Services & Products

Live Single Cell Functional Analysis
Optofluidic Instruments
Proteomic Barcoding Technology
Antibody Discovery Kits
Cell Line Development Kits
T Cell Profiling Kits
Software for Cell Analysis and Visualization

Target Customers

Biotechnology Companies Pharmaceutical Companies Academic Researchers Translational Researchers Immunology Specialists Oncology Researchers

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing $50.00M 3
BlackRock Ally Bridge Group Perceptive Advisors
BlackRock, Ally Bridge Group +1
07 Jan 2021
Series D $85.00M 3
BlackRock Ally Bridge Group Perceptive Advisors
BlackRock, Ally Bridge Group +1
07 Jan 2021
Grant $2.00M 1
National Institute on Aging
09 Jun 2020
Series C $20.00M 6
Advantage Capital Partners Connecticut Innovations Ironwood Capital Connecticut
Advantage Capital Partners, Connecticut Innovations +4
09 Jan 2020
Grant $2.00M 1
National Cancer Institute SBIR Development Center
23 Oct 2019
Grant $4.00M 1
National Cancer Institute SBIR Development Center
21 Jun 2019
Series C $25.00M 6
Advantage Capital Partners Connecticut Innovations Ironwood Capital Connecticut
Advantage Capital Partners, Connecticut Innovations +4
14 May 2019
Series B $13.50M 5
Advantage Capital Partners Connecticut Innovations Ironwood Capital Connecticut
Advantage Capital Partners, Connecticut Innovations +3
25 Sep 2017
Series B Undisclosed 1
Advantage Capital Partners
Advantage Capital Partners
03 Nov 2016
Venture Round $2.35M -
28 May 2015

View All 11 Funding Rounds

IsoPlexis Alternatives & Competitors

View All Alternatives
IsoPlexis vs
Mission Bio
Mission Bio United States

The Tapestri® Platform; the only technology that provides single-cell targeted DNA sequencing at sin...

Growth
88 employees
Biotechnology, Health Care
Compare IsoPlexis vs Mission Bio
IsoPlexis vs
Singular Genomics
Singular Genomics United States

Accelerating multiomics for the advancement of science and medicine.

Acquired
163 employees
Biotechnology, Health Care
Compare IsoPlexis vs Singular Genomics
IsoPlexis vs
Kypha
Kypha United States

Precision Immune Monitoring Delivered

Venture round
15 employees
Biotechnology, Health Care
Compare IsoPlexis vs Kypha
Also compare with: IsoPlexis vs Cellply Cellply View all alternatives

FAQ About IsoPlexis

Powerful Biology Accelerating the Future of Medicine
IsoPlexis was founded in 2013.
IsoPlexis is headquartered in Branford, United States.
IsoPlexis operates in Biotechnology, Health Care, Health and Wellness and Medical Devices. Its work centres on Life Science Technology, Single-Cell Detection, Immune Medicine and Curative Medicines. Its customers include Biotechnology Companies, Pharmaceutical Companies and Academic Researchers.
IsoPlexis has a B2B, Platform and SaaS business model. Its revenue comes from Product Sales, Subscription and Usage Based.
IsoPlexis has approximately 65 employees.
IsoPlexis has completed 11 funding rounds, raising a total of $205.10M. The latest funding stage is Series D.
IsoPlexis offers: Live Single Cell Functional Analysis, Optofluidic Instruments, Proteomic Barcoding Technology, Antibody Discovery Kits, Cell Line Development Kits, T Cell Profiling Kits, Software for Cell Analysis and Visualization.
Top alternatives and competitors to IsoPlexis include Mission Bio, Singular Genomics, Kypha, Akoya Biosciences, Inc., Partillion Bioscience. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
IsoPlexis and Mission Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for IsoPlexis, https://bouncewatch.com/company/isoplexis, updated 15 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes